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Non-resectable colorectal liver metastases (CLMs) are generally 
considered an absolute contraindication for liver transplantation, 
because of poor outcomes reported during the 1990s.[1] However, a 
2013 Norwegian pilot study by Hagness et al.[1] transplanted livers 
in 21 patients with non-resectable CLMs, and reported excellent 
oncological outcome and a 60% 5-year survival. This result far exceeds 
that which is obtained with chemotherapy.[1] Although a promising 
development, consensus is that larger studies with longer follow-up 
times, in different cohorts, are needed to validate the results and to 
support CLMs as an indication for liver transplant, or not.[2]
In South Africa (SA), an upper-middle income country (UMIC),[3] 
a relatively small number of organ transplants are performed 
annually. In recent years, teams of committed academic surgeons and 
physicians have developed, or adopted, new transplant techniques, 
in a bid to extend this treatment to a larger number of patients. 
However, the supply of donor organs in SA falls far short of the 
demand for them. Wits Donald Gordon Medical Centre (WDGMC) 
is a tertiary academic hospital in Johannesburg, and is one of three 
hospitals in SA offering liver transplantation. As it falls within the 
University of the Witwatersrand (Wits) hospital complex, all research 
taking place at WDGMC requires approval from the Wits Human 
Research Ethics Committee (Medical) (HREC(M)). 
This article reports on the deliberations of the Wits HREC(M) that 
eventually led to the approval of a research project to transplant, and 
prospectively follow-up, patients presenting with CLMs at WDGMC. 
To date, to the best of our knowledge, Columbia is the only other 
UMIC that has performed a transplant on a patient presenting with 
CLMs.[4] Both the Norwegian and Columbian articles recorded ethics 
committee approvals, but no details were mentioned.[1,4]
Given that a number of other UMICs, including Belarus, Brazil, China, 
Iran and Romania host liver transplant programmes, it is foreseeable 
that they may consider similar research. We hope that this article may 
be useful for HRECs at other SA transplant centres and in UMICs that 
are similar to SA, where transplant indications and outcomes may 
differ from those in high-income countries. 
The case
In early 2015, we were approached by Patient A, a well-informed 
medical doctor diagnosed with non-resectable CLMs. Patient A, who 
had searched the internet for information, requested consideration 
for liver transplantation, based on the outcome of Hagness et al.[1] and 
because he fitted the inclusion criteria. The WDGMC Clinical Research 
Office advised the transplant team, and forwarded an application 
to undertake the liver transplant as a case study to the HREC(M). 
The request was urgent as Patient A required transplant work-up, 
so the matter was debated by the four co-chairs of the HREC(M), in 
collaboration with the WDGMC team. All decisions were subsequently 
ratified by the full HREC(M) (ref. nos. M150362 and M151037). The 
application was made under section 37 of the 2013 Declaration 
of Helsinki.[5] This has been the basis for a number of international 
studies proposing to use new or non-indicated modalities in patients 
who have exhausted conventional management options, and states:
‘In the treatment of an individual patient, where proven 
interventions do not exist or other known interventions have been 
ineffective, the physician, after seeking expert advice, with informed 
consent from the patient or a legally authorised representative, 
may use an unproven intervention if in the physician's judgement 
it offers hope of saving life, re-establishing health or alleviating 
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suffering. This intervention should subsequently be made the object 
of research, designed to evaluate its safety and efficacy. In all cases, 
new information must be recorded and, where appropriate, made 
publicly available.’[5] 
The HREC(M) felt that these terms were sufficient for approving the 
case, with the condition that the principal investigator report back 
and formalise the intervention as a research study, if applicable. In 
making this decision, several points of ethics were deliberated.
Scarcity of donor organs in SA
Studies using scarce resources (such as donor livers) to treat a 
condition for which such management is not yet indicated pose 
unique ethical challenges. Hagness et al.[1] justified their study based 
on a surplus of donor livers in Norway. In SA, the ethical challenges are 
heightened, as the supply of donor organs falls short of the demand 
for them. Donor organs are usually allocated to listed individuals on 
the basis of need (‘sickest person first’ principles), and depending on 
the size of graft required and blood group compatibility.
Because the waiting list for liver transplants in SA is relatively short, 
the HREC(M) concluded that it would be ethically sound to allocate 
a marginal (expanded criteria) graft – which had been refused by 
all other centres countrywide – to Patient A. A marginal graft would 
not usually be suitable for implantation, owing to factors such as 
markedly elevated liver function tests, older age or HIV-positive 
status of the donor or excessive macrosteatosis on hepatic biopsy. 
This decision may have been different if the liver waiting list was 
much longer, with other patients who could have benefitted from a 
marginal graft – as is often the case with patients who require kidney 
transplantation.
There was no comparable precedent from other UMICs for the 
decision to allow a marginal graft for Patient A at the time. In the 
more recent case of a liver transplant for CLMs in Columbia, it is 
unclear whether the graft was marginal (the publication states only 
that the graft was from a 22-year-old male in cold ischaemia for 7.5 
hours). It is possible that the Columbian centre had a surplus of donor 
livers.[4] Until the procedure is validated by further research, it seems 
that offering patients with CLMs marginal grafts is the only ethical 
solution in the SA context of organ scarcity. 
Patients already listed for liver transplants
A number of patients with recognised indications are waiting for 
liver transplants at any given time. Because liver transplantation is 
not accepted for CLMs, it was essential that these patients were not 
disadvantaged by the decision to perform the transplant on Patient 
A. Recognising the imperative to balance the best interests of listed 
patients with the best interests of Patient A, the HREC(M) stipulated 
that Patient A may receive a donor liver only if there was no other 
suitable recipient for the graft, countrywide. This decision effectively 
meant that irrespective of model for end-stage liver disease (MELD) 
score or urgency, Patient A would not be prioritised for transplant.
Risks and benefits to the patient
Careful analysis concluded that for Patient A, the anticipated benefits 
of transplant (prolonged life, possibly by several years) categorically 
outweighed the concomitant risks (contracting HIV, life-long 
medication, rejection). The fact that Patient A was a medical doctor 
and perhaps better able to appreciate the extent of the risk was 
also a consideration for informed consent. Nonetheless, as per SA 
ethics guidelines,[6] HREC(M) stipulated that Patient A should be fully 
informed of the potential risks involved in receiving a marginal graft, 
and their consequences. 
Questions of cost
Identifying who will bear the financial costs of clinical research is 
essential for HRECs. SA ethics regulations stipulate that no research 
costs should be incurred by a participating institution.[6] Liver trans-
plantation is very expensive, and the HREC agreed that either Patient 
A’s medical scheme should fund the transplant on an ad hoc basis, 
or the patient would need to pay his own medical expenses. In the 
latter case, the HREC stipulated that Patient A must be notified of all 
potential costs, in order to make an informed decision. Ultimately, the 
research procedure was authorised by the medical scheme.
Brief concluding remarks and study 
progress
Patient A received a transplant from a 75-year-old donor in August 
2015. Based on encouraging short-term findings, a submission was 
made to the HREC(M) to formalise the protocol as a research study, 
and the request was approved. Recruitment for the study is ongoing, 
and the study process is illustrated in Fig. 1. 
The mandates to further evidence-based medicine (EBM) on the 
one hand, and protect research participants on the other, can present 
HRECs with something of a catch 22 – exemplified by this case. EBM is 
constantly evolving, as studies identify superior treatment modalities; 
however, these studies may often seem precipitous at the outset, 
with too many risks to participants. Nonetheless, it is essential that 
they take place in order for EBM to evolve. This may require difficult 
decisions, which are not always widely acceptable. There are a 
Fig. 1.  Study process.
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number of examples of evolving EBM in liver transplant research. Studies 
of transplant patients with CLMs may follow the same pattern, and 
should be judiciously encouraged. Primary hepatocellular carcinoma is 
now considered an indication for liver transplant because of improved 
screening and the development of standardised criteria (Milan) that have 
facilitated better outcomes. The same goes for cholangiocarcinoma, 
with ~65% of patients recurrence-free after 5 years, having undergone 
improved neoadjuvant therapy followed by liver transplant.[2]
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